Mineralys Therapeutics, Inc. (MLYS)
MLYSNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$16.18
+0.3721 (+2.35%) today
Closed, Nov 10, 4:00 PM ET
- Market cap
- $1.37bn
- P/E
- –
- EPS, last 4 quarters
- $-4.36
- Dividend yield
- –
- Day range
- –
- 52-week range
- $14.91 to $47.65
- Average volume
- 1.60m
- Previous close
- $15.81
Analysts
9 coveringBuy8 buy, 1 hold, 0 sell
Targets a year out average $46.86, +189.6% from here
Earnings
next estimate $-0.6500Next report
Dec 2025
+29.8%
Mar 2026
+7.8%
Jun 2026
-400.0%
Sep 2026
-20.8%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$38.28m | -$45.34m | -$246.04m | -$60.09m |
| Net income | -$32.23m | -$39.34m | -$241.07m | -$57.33m |
News
8 latest- Mineralys' Lorundrostat Sustains Blood Pressure Reduction Through 48 Weeks RTTNews · 1 day ago
- Mineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateFintel · 6 days ago
- What Mineralys Therapeutics (MLYS) Said on Its Q3 Earnings CallMarketBeat · 6 days ago
- Mineralys Therapeutics, Inc. Terminates License Agreement and Acquires Lorundrostat IP from Tanabe PharmaFintel · Oct 30, 2026
- Mineralys Reports Phase 2 Lorundrostat Data In Chronic Kidney Disease RTTNews · Oct 28, 2026
- Mineralys (MLYS) Q2 2026 Earnings Call TranscriptThe Motley Fool · Aug 18, 2026
- Mineralys Therapeutics Q2 Earnings Call HighlightsMarketBeat · Aug 11, 2026
- After-Hours Earnings Report for August 11, 2026 : LITE, FNV, CRWV, SMCI, CAVA, IFS, HRB, FLY, MLYS, NN, TGLS, TSHANASDAQ.com · Aug 11, 2026
The company
Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- mineralystx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.